Financhill
Sell
5

PRTA Quote, Financials, Valuation and Earnings

Last price:
$13.65
Seasonality move :
10.47%
Day range:
$13.53 - $14.50
52-week range:
$11.70 - $41.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.61x
P/B ratio:
1.39x
Volume:
1.4M
Avg. volume:
661.4K
1-year change:
-61.89%
Market cap:
$745.3M
Revenue:
$91.4M
EPS (TTM):
-$2.48

Analysts' Opinion

  • Consensus Rating
    Prothena Corp PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $59.00, Prothena Corp PLC has an estimated upside of 259.21% from its current price of $13.85.
  • Price Target Downside
    According to analysts, the lowest downside price target is $24.00 representing 100% downside risk from its current price of $13.85.

Fair Value

  • According to the consensus of 5 analysts, Prothena Corp PLC has 259.21% upside to fair value with a price target of $59.00 per share.

PRTA vs. S&P 500

  • Over the past 5 trading days, Prothena Corp PLC has underperformed the S&P 500 by -7.26% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Prothena Corp PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Prothena Corp PLC revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Prothena Corp PLC reported revenues of $970K.

Earnings Growth

  • Prothena Corp PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Prothena Corp PLC reported earnings per share of -$1.10.
Enterprise value:
226M
EV / Invested capital:
--
Price / LTM sales:
5.61x
EV / EBIT:
--
EV / Revenue:
1.69x
PEG ratio (5yr expected):
-0.07x
EV / Free cash flow:
-1.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-19.93%
Net Income Margin (TTM):
-98.86%
Return On Equity:
-23.56%
Return On Invested Capital:
-23.56%
Operating Margin:
-6857.01%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $5.2M $141M $133.4M $84.9M $970K
Gross Profit -- -- -- -- --
Operating Income -$164.6M -$112.6M -$168.2M $10.3M -$66.5M
EBITDA -$159.6M -$111.9M -$167.2M $10.5M -$66.3M
Diluted EPS -$3.34 -$1.42 -$2.48 $0.38 -$1.10
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $320.5M $607.5M $524.6M $690.6M $535M
Total Assets $355.8M $632.7M $554.4M $746.9M $595.3M
Current Liabilities $21.7M $29.2M $50.6M $53.4M $46.4M
Total Liabilities $146.3M $142.2M $149.8M $129.7M $60.9M
Total Equity $209.5M $490.5M $404.6M $617.2M $534.4M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$126.3M -$87.8M -$153.3M $9.5M -$45.2M
Cash From Investing -$632K -$1.4M -$1.8M -$442K -$9K
Cash From Financing $22.5M $265.4M $2.1M $2.7M $333K
Free Cash Flow -$126.9M -$89.3M -$155.1M $9.1M -$45.2M
PRTA
Sector
Market Cap
$745.3M
$47.7M
Price % of 52-Week High
33.34%
46.05%
Dividend Yield
0%
0%
Shareholder Yield
0.04%
-0.74%
1-Year Price Total Return
-61.89%
-33.33%
Beta (5-Year)
0.102
0.760
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $15.20
200-day SMA
Sell
Level $19.93
Bollinger Bands (100)
Sell
Level 0 - 0
Chaikin Money Flow
Sell
Level --
20-day SMA
Sell
Level $14.31
Relative Strength Index (RSI14)
Sell
Level 44.18
ADX Line
Neutral
Level 0
Williams %R
Neutral
Level -63.9262
50-day SMA
Sell
Level $15.47
MACD (12, 26)
Sell
Level -0.15
25-day Aroon Oscillator
Buy
Level 4
On Balance Volume
Neutral
Level --

Financial Scores

Buy
Altman Z-Score (Annual)
Level (6.9284)
Buy
CA Score (Annual)
Level (-0.1606)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (0.3204)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Stock Forecast FAQ

In the current month, PRTA has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The PRTA average analyst price target in the past 3 months is $59.00.

  • Where Will Prothena Corp PLC Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Prothena Corp PLC share price will rise to $59.00 per share over the next 12 months.

  • What Do Analysts Say About Prothena Corp PLC?

    Analysts are divided on their view about Prothena Corp PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Prothena Corp PLC is a Sell and believe this share price will drop from its current level to $24.00.

  • What Is Prothena Corp PLC's Price Target?

    The price target for Prothena Corp PLC over the next 1-year time period is forecast to be $59.00 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is PRTA A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Prothena Corp PLC is a Buy. 3 of 5 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of PRTA?

    You can purchase shares of Prothena Corp PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Prothena Corp PLC shares.

  • What Is The Prothena Corp PLC Share Price Today?

    Prothena Corp PLC was last trading at $13.65 per share. This represents the most recent stock quote for Prothena Corp PLC. Yesterday, Prothena Corp PLC closed at $13.85 per share.

  • How To Buy Prothena Corp PLC Stock Online?

    In order to purchase Prothena Corp PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Booking Holdings Stock Undervalued?
Is Booking Holdings Stock Undervalued?

There is a lot of humdrum in the market about…

Broadcom vs American Express: Which Is Best?
Broadcom vs American Express: Which Is Best?

Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…

Why Is Adobe Stock Dropping?
Why Is Adobe Stock Dropping?

Why is Adobe stock dropping? A combination of underwhelming fiscal…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Sell
25
DRUG alert for Jan 3

Bright Minds Biosciences [DRUG] is up 13.55% over the past day.

Buy
56
QMCO alert for Jan 2

Quantum [QMCO] is up 0.83% over the past day.

Buy
88
BMA alert for Jan 3

Banco Macro SA [BMA] is up 12.94% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock